Virtual | September 22-24, 2022
THURSDAY, SEPTEMBER 22, 2022
8:00 AM – 10:06 AM
SESSION I: PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
State of the Art in Prostate Cancer Screening
10:30 AM – 12:45 PM
SESSION I: PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
12:45 PM – 1:40 PM
LUNCH BREAK
1:40 PM – 2:10 PM
SESSION I. PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Transperineal Prostate Biopsy — Current and Future Clinical Role
NCCN Guidelines for Early Detection of Prostate Cancer 2022
3:20 PM – 6:00 PM
SESSION II. CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Liquid Markers – Proteomics and Germline Genome
Tissue-Based Genetic Cancer Profiling Overview
Pathology Overview
Current and Future Directions in Risk Assessment: Should Gleason 6 (GG1) be Considered Cancer?
In Vivo Imaging
FRIDAY, SEPTEMBER 23, 2022
8:00 AM – 10:10 AM
SESSION II: CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER (Continued)
In Vivo Imaging (Continued)
Urologic Perspective on the Current and Emerging Role of Multi-Modality Imaging and Radiogenomics
Integration of Precision Diagnosis and Precision Treatment
10:10AM – 11:30 AM
SESSION II: CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER (Continued)
Integration of Precision Diagnosis and Precision Treatment Cont.
11:30 AM – 1:15 PM
LUNCH BREAK
1:15 PM – 3:35 PM
SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
4:00 PM – 6:00 PM
SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Molecular and Multi-Modality Imaging and Theranostics
SATURDAY, SEPTEMBER 24, 2022
8:00 AM – 9:40 AM
SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT
Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
10:10 AM – 11:00 AM
SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT
Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
11:00 AM – 1:00 PM
LUNCH BREAK
1:00 PM – 2:20 PM
PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTIMODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
2:40 PM – 3:30 PM
PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER
3:30 PM – 3:45 PM:
PRESENTATION OF WINNING ABSTRACTS
3:45 PM – 5:00 PM
SUMMARY PANEL DISCUSSION – SUMMIT HIGHLIGHTS
6:00 ADJOURN